To validate established cutoff levels of thymidylate synthase (TS) and excision repair cross-complementing (ERCC-1) intratumoral mRNA expressions in tumor samples from metastatic colorectal cancer (mCRC) patients treated with PTK787/ZK222584 (PTK/ZK). From 122 samples of patients with mCRC enrolled in CONFIRM-1 (Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases) or CONFIRM-2, mRNA was isolated of microdissected formalin-fixed paraffin-embedded samples and quantitated using TaqMan-based technology. Existing TS and ERCC-1 cutoff levels were tested for their prognostic value in first-line and second-line therapy. TS expression was associated with overall survival (OS) in first-line, but not second-line therapy. ERCC-1 was associated with OS in patients treated with first-line and second-line FOLFOX4. In first-line FOLFOX4, combination of high TS and/or high ERCC-1 was associated with shorter OS. A correlation was observed between ERCC-1 expression and benefit from PTK/ZK þ FOLFOX4 treatment. TS and ERCC-1 expression is associated with clinical outcome in mCRC. Baseline TS and ERCC-1 levels may allow the selection of patients who benefit from FOLFOX4 chemotherapy.
Introduction
Colorectal cancer (CRC) is the third most common cancer in the United States. In 2009, over 146 000 patients were diagnosed with CRC, with 49 920 resultant deaths. 1 Introduction of novel cytotoxic and targeted agents into the treatment strategies for patients with metastatic CRC (mCRC) has significantly improved overall survival (OS) in the past few years; however, not all patients respond to chemotherapy because of the genetic composition of the tumor and individual host toxicity.
With increasing treatment options available for these patients, it is essential to develop biomarkers to identify patients who might benefit from specific therapies. Biomarkers associated with benefit from chemotherapy are often involved in pathways such as the cell cycle, apoptosis, epithelial and vascular growth factor pathways, nucleoside synthesis or DNA repair. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] We have had no validated prognostic marker clinically available until recent data suggested that BRAF mutation may be prognostic for mCRC. 12, 13 We need validated predictive and prognostic markers to tailor chemotherapy for increased efficacy and decreased toxicity. The excision repair cross-complementing (ERCC-1) pathway proteins have an important role in repairing DNA damage from platinum treatment by nucleotide excision and repair. First, the excision process removes the modified nucleotides of the DNA, including adjacent nucleotides, and then the repair synthesis process restores the DNA by means of DNA polymerase activity.
14,15 ERCC-1 gene expression has been shown to be associated inversely with response to platinum-based therapies and survival as an independent function. [16] [17] [18] On the basis of previous studies, we have established cutoff levels associated with benefit from platinum-based chemotherapy in colon, gastric, head/ neck, bladder and non-small-cell lung cancer. 16, 19 Patients with ERCC-1 expression levels higher than 1.73 have lower response rates, shorter progression-free survival (PFS) and shorter OS in CRC. 16, 19 Fluoropyrimidines are still the most commonly used chemotherapeutic agents for the treatment of CRC. In several studies, thymidylate synthase (TS) gene expression has been reported to be a predictive and prognostic marker for patients with mCRC treated with fluoropyrimidinebased therapy. 8, 11, [20] [21] [22] [23] Popat et al. 24 showed in a metaanalysis that TS gene expression is a prognostic marker in patients with mCRC. On the basis of previous studies, the cutoff of 4.0 was established for TS mRNA expression in colon cancer. We have shown previously that patients with high TS gene expression have lower response rates, shorter PFS and shorter OS. 16, 25 We tested these two established cutoff levels in two randomized, double-blind, placebo-controlled, Phase III studies (CONFIRM-1 and CONFIRM-2; Colorectal Oral Novel Therapy for the Inhibition of Angiogenesis and Retarding of Metastases) in patients with mCRC who were receiving first-line (CONFIRM-1) or second-line (CONFIRM-2) chemotherapy with folinic acid (leucovorin), 5-fluorouracil, oxaliplatin (FOLFOX4) and either PTK/ZK or placebo.
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PTK787/ZK222584 (Vatalanib or PTK/ZK) is an orally active angiogenesis inhibitor that offers a novel approach to inhibiting tumor growth. 27 Although the primary end point for OS was not met in the CONFIRM-1 and -2 trails, PTK/ZK improved PFS significantly in the overall population. 28 Subgroup analyses of patients with increased lactate dehydrogenase in the CONFIRM trials suggested a greater clinical benefit when PTK/ZK was added to a standard FOLFOX4 therapy regimen compared with FOLFOX4 plus placebo. 29 The aim of our study was to validate established cutoff levels of TS and ERCC-1 gene mRNA expressions in patients with mCRC enrolled in these two prospective, Phase III, first-line and second-line studies.
Materials and methods

Patients and specimens
Data and tissue collection were in accordance with the regulations of the local ethics committee. In the initial CONFRIM-1 and -2 trails, more than 2000 patients were enrolled at more than 200 centers. A total of 128 formalinfixed paraffin-embedded (FFPE) samples of the primary tumor from patients enrolled in CONFIRM-1 (first-line study) and CONFIRM-2 (second-line study) were available for TS and ERCC-1 analysis. Six FFPE samples were excluded because of insufficient RNA amounts due to sample quality. We had sufficient RNA from 122 FFPE samples and included these in this study. The FFPE tumor samples were collected at the time of diagnosis before first-line chemotherapy. We tested tumor samples from 59 patients enrolled in CONFIRM-1 (29 patients treated with FOLFOX4 plus placebo, 30 patients treated with FOLFOX4 plus PTK/ZK) and 63 patients enrolled in CONFIRM-2 (37 patients treated with FOLFOX4 plus placebo, 26 patients treated with FOLFOX4 plus PTK/ZK) ( Figure 1 and Table 1 ). In the first-line study, 42 of 59 samples (71%) were male patients and 17 of 59 samples (29%) were from female patients; in the second-line study, 48 of 63 samples (76%) were from male patients and 15 of 63 samples (24%) were from female patients. The median age of patients was 61 years (range: 28-82) in the first-line study and 64 years (range: 42-83) in the second-line study.
Microdissections FFPE tissues from patients in the CONFIRM-1 and -2 trials were dissected as previously described by Azuma et al.
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The paraffin-embedded tumor blocks were reviewed by a pathologist for quality and tumor content. Slides (10 mm thick) were obtained from the identified areas with the highest tumor concentration and were mounted on uncoated glass slides. For histological diagnosis, three sections representative of the beginning, middle and end of the tissue were stained with hematoxylin and eosin stain using the standard method. Before microdissection, sections were deparaffinized in xylene for 10 min; hydrated with 100, 95 and 70% ethanol; and washed in H 2 O for 30 s. After this process, the sections were stained with nuclear fast red (American Master Tech Scientific, Lodi, CA, USA) for 20 s and rinsed in H 2 O for 30 s. Samples were then dehydrated with 70% ethanol, 95 ethanol and 100% ethanol for 30 s, each followed by xylene for 10 min. The slides were then air-dried completely. Laser capture microdissection (PALM Microlaser Technologies AG, Munich, Germany) was performed on all tumor samples to ensure that only tumor cells were dissected. 30 The dissected particles of tissue were transferred to a reaction tube containing 400 ml of RNA lysis buffer.
mRNA isolation RNA isolation from paraffin-embedded samples was performed according to a proprietary procedure defined by Response Genetics (Los Angeles, CA, USA; United States patent number 6 248 535). After RNA isolation, cDNA was prepared from each sample as described previously.
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Quantification by real-time polymerase chain reaction Quantitation of TS, ERCC-1 and an internal reference (b-actin) cDNA was performed using a fluorescence-based real-time detection method (ABI PRISM 7900 Sequence detection System (TaqMan) Perkin-Elmer (PE) Applied Biosystems, Foster City, CA, USA) as described previously. 33 . The polymerase chain reaction mixture consisted of 1200 nM of each primer; a 200 nM probe; 0.4 U of AmpliTaq Gold polymerase; 200 nM of dATP, dCTP, dGTP and dTTP; 3.5 mM MgCl 2 ; and 1 Â TaqMan buffer A containing a reference dye added to a final volume of 20 ml (all reagents from PE Applied Biosystems). Cycling conditions were 50 1C for 2 min and 95 1C for 10 min, followed by 46 cycles at 95 1C for 15 s and 60 1C for 1 min. The TS primers and probe sequences used were as follows: forward primer, GCCTCGG TGTGCCTTTCA; reverse primer, CCCGTGATGTGCGCAAT; and probe, 6FAM-TCGCCAGCTACGCCCTGCTCA. The ER CC-1 primers and probe sequences used were as follows: forward primer, GGGAATTTGGCGACGTAATTC; reverse primer, GCGGAGGCTGAGGAACAG; and probe, 6FAM-CAC AGGTGCTCTGGCCCAGCACATA. The b-actin primers and probe sequences used were as follows: forward primer, GAGCGCGGCTACAGCTT; reverse primer, TCCTTAATGTCA CGCACGATTT; and probe, 6FAM-ACCACCACGGCCGAG CGG.
For each sample, parallel TaqMan polymerase chain reactions were performed for each gene of interest and the b-actin reference gene to normalize for input cDNA. The obtained ratio between the values provides relative gene expression levels for the gene locus investigated.
Statistical analyses OS was calculated as the time from the first day of randomization until death from any cause or until the date of the last follow-up. If a patient had not progressed or died, PFS was censored at the time of the last follow-up. World Health Organization performance status was defined as 0 ¼ fully active and able to perform without restriction, 1 ¼ restricted physically strenuous activity and 2 ¼ capable of self-care, but unable to work.
SPSS Statistics version 17.0 (SPCC, Chicago, IL, USA) was used for all statistical analyses. TaqMan analyses yield values that are expressed as ratios between two absolute measurements (gene of interest/internal reference gene). The Mann-Whitney U-test was used to test for significant associations between the continuous test variable gene expression and dichotomous variables. The Kruskal-Wallis test was used to test for significant differences in gene expression within multiple groups. The already validated and used cutoff values of TS X4 and ERCC-1 X1.73 were chosen to group the patients into high or low TS and ERCC-1 expressors. These cutoff values have been established over numerous analyses of colon tumor samples at Response Genetics. 16, 34 On the basis of the ratio 80/20 for ERCC-1 low/high, a bootstrap testing was used to test the optimalness of this cutoff. Response Genetics used a standardized calculation method, which was given as Danenberg Tumor Profile. Cox regression adjusted for performance status and Kaplan-Meier functions were used to estimate the survival probabilities. Correlations between the analyzed genes were calculated using two-tailed Spearman's r test. Interactions between ERCC-1 expression and PTK/ZK treatment were tested on OS by comparing likelihood ratio statistics between the baseline and nested Cox proportional hazards models that included the multiplicative product terms. The level of significance was set to Po0.05.
Role of the study sponsor
The sponsor of the study was responsible for the identification of the tumor samples and shipment of the FFPE samples to the laboratory. The sponsor had no involvement with the study design, interpretation or analysis of the data. Figure S1) . Dividing the patients into various categories of ERCC-1 and TS gene expression according to the respective cutoff values used in this study gave the results shown in Table 2 . Using the established cutoff values for ERCC-1 and TS, no significant association with gender, performance status, treatment arm or first-line vs second-line treatment was found.
TS and ERCC-1 mRNA expression and survival First-line FOLFOX4 treatment. In patients treated first line with FOLFOX4 (n ¼ 29), the TS and ERCC-1 gene expression cutoff levels tested had significant associations with OS.
Patients with high TS mRNA expression compared with low TS mRNA expressors had a significantly reduced OS (P ¼ 0.002, Cox regression; hazard ratio (HR) ¼ 0.12; 95% confidence interval (CI) ¼ 0.03-0.47; Table 3 ). The median survival in patients with low TS mRNA expression was 39.3 months compared with 12 months in high TS expressors. High ERCC-1 mRNA expressors had a significantly reduced OS compared with low ERCC-1 mRNA expressors (P ¼ 0.025, Cox regression; HR ¼ 0.27; 95% CI ¼ 0.09-0.85) (Figure 2a) . The median survival was 33.1 months in patients with low ERCC-1 expression and 16 months in the patients with high ERCC-1 mRNA expression. When comparing patients in which both genes were low with those in which TS, ERCC-1 or both were high, the latter group was found to have a significantly reduced OS (P ¼ 0.001, Cox regression; HR ¼ 0.16; 95% CI ¼ 0.05-0.48) (Figure 3 ). The median survival was 37 months in patients with both genes low expressed and 15.6 months in the patients with one or both high expressed. 
Discussion
The aim of this study was to validate whether the published cutoff levels of TS and ERCC-1 are associated with clinical outcomes in patients with mCRC who are treated with FOLFOX-based chemotherapy. Although TS and ERCC-1 mRNA expression have been previously reported as predictive and prognostic markers in CRC, 16, 17, 20, 21, 34 there are no validation data available for first-line or second-line studies in mCRC and no clear evidence that these markers remain prognostic when FOLFOX is combined with PTK/ZK.
We were able to confirm that TS and ERCC-1 mRNA expressions are associated significantly with outcomes of FOLFOX chemotherapy. TS mRNA expression was associated significantly with PFS and OS in patients treated with first-line FOLFOX4, thus confirming similar findings by Kim et al. 35 TS mRNA expression also was associated with OS in patients treated with first-line FOLFOX4 plus PTK/ZK, but not in patients receiving the same treatment as second-line therapy, suggesting that TS gene expression may be modulated with exposure to 5-fluorouracil-based chemotherapy. TS mRNA expression, measured before the first-line treatment, is not useful for the prediction of a second-line treatment. Interestingly, ERCC-1 mRNA expression was prognostic for patients who received FOLFOX4 in both first-line and second-line settings. However, ERCC-1 was not significantly associated with PFS in the first-line setting in this study in FOLFOX4-treated patients, which may be due to the limited numbers of our subgroup analysis. High intratumoral ERCC-1 mRNA expression was expected to be associated with reduced OS for patients treated with first-line FOLFOX4, but this effect remained for second-line FOLFOX4 treatment, suggesting that DNA platination remains a mechanism for FOLFOX4 efficacy in first-line and second-line settings and is not altered by exposure to irinotecan and 5-flourouracil-based therapies. These data are consistent with published data by Shirota et al. 16 and underscore the importance of ERCC-1 mRNA expression and association with clinical outcome in patients treated with FOLFOX4 therapy.
ERCC-1 mRNA expression was not associated with OS in patients treated with FOLFOX plus PTK/ZK, suggesting a potential interaction of ERCC-1 with efficacy of PTK/ZK. The significant interaction may indicate that patients with low ERCC-1 expression did not benefit from the addition of PTK/ ZK to FOLFOX4. There was no interaction with TS mRNA expression and PTK/ZK. The interaction of ERCC-1 mRNA expression and PTK/ZK efficacy may be due to pathways that regulate DNA repair and genes involved in the angiogenic pathway, such as vascular endothelial growth factor receptor-1 (VEGFR1) and VEGFR2. In fact, in another study, we have shown a significant correlation between ERCC-1 and VEGFR1 and VEGFR2 gene expression independent of mutant KRAS status. 36 Recent data have shown that KRAS mutation is associated with elevated ERCC-1 and VEGF mRNA expression, 37 indicating that KRAS may be a link between these two pathways, similar to the link between ERCC-1 mRNA expression and EGFR mutation in non-small cell lung cancer. 38 These data suggest that, with increased sensitivity to anti-VEGF treatment, there is an increased resistance to oxaliplatin, which might explain the failure to improve OS in the combination treatments of FOLFOX4 plus PTK/ZK, FOLFOX plus bevacizumab or FOLFOX plus AZD2171. [39] [40] [41] [42] [43] Using our previously established cutoffs, we showed that low TS and low ERCC-1 mRNA expressions found in approximately 70% of the patients were associated with outcomes of FOLFOX chemotherapy, thus validating these cutoff levels. 16 In all, 15-20% percent of patients with mCRC have high tumorous TS mRNA expression, and approximately 20-25% have a high tumorous ERCC-1 mRNA expression, which concurs with earlier findings. 16, 44 TS and ERCC-1 mRNA expressions were correlated in this study, consistent with other reports, 17 perhaps partially accounting for the fact that TS and ERCC-1 mRNA expressions are associated with clinical outcomes in patients treated with 5-flourouracil-or oxaliplatin-based chemotherapy.
On the basis of our study results, patients with high TS and/or high ERCC-1 mRNA expression may not be considered for FOLFOX chemotherapy; however, data suggest that tumors with high ERCC-1 levels may benefit from FOLFIRI treatment. Our data suggest for the first time that patients with high ERCC-1 may benefit from antiangiogenic-based therapy. Our findings suggest that intratumoral ERCC-1 mRNA expression may be a useful and potent biomarker not only for first-line, but also for secondline chemotherapy decisions. Further investigations of the interaction between ERCC-1 mRNA expression and the benefit of PTK/ZK in combination with FOLFOX4 treatment are warranted.
Future perspective
The identification and validation of prognostic markers in colon cancer will be important tools in the future to develop personalized therapies. This study validated intratumoral TS and ERCC-1 gene expression levels in a prospective Phase III clinical trial for patients with metastatic CRC. These markers may be helpful to select more effective chemotherapy for patients with mCRC. Our data also revealed for the first time that patients with high ERCC-1 may benefit from anti-VEGF/VEGFR-based therapy, which warrants further investigations into the interaction of DNA repair and angiogenesis.
Conclusions
Our data confirmed that gene expression levels of TS and ERCC-1 are associated with clinical outcome. TS and ERCC-1 gene expression levels may allow the selection of patients who will likely benefit from FOLFOX4 chemotherapy. ERCC-1 shows a significant interaction with efficacy of PTK, suggesting that combination of oxaliplatin and anti-VEGFR may not be a successful combination owing to the co-regulation of VEGFR and ERCC-1. The molecular understanding of these interactions is critical to allow more effective drug development.
